Sanofi Q3 2025 Financial and Operational Highlights

Sanofi reported a 7.0% increase in Q3 2025 sales at constant exchange rates (CER), driven by strong performance in its Pharma launches and Dupixent, which exceeded €4 billion in quarterly global sales for the first time. The company's business earnings per share (EPS) grew by 13.2% at CER. Key highlights include a 57.1% increase in Pharma launch sales, reaching €1.0 billion, and a 26.2% growth in Dupixent sales. Sanofi also achieved significant pipeline milestones, including regulatory approvals for Wayrilz in the US and Tzield in China. The company reiterated its 2025 guidance, anticipating high single-digit sales growth and a strong rebound in business EPS.